An ultra-sensitive ctDNA platform that fits how you actually work.
Detect signal at parts-per-million in samples your current platform calls negative. Run it as a service from our EU-accredited lab, or bring SiMSen-Seq in-house on your own instruments. Same chemistry, same sensitivity, your decision on delivery.
✓ ISO 15189 compliant · Open pipeline, raw data access · EU-based
Five things you cannot buy off the shelf elsewhere.
01
Sensitivity
You detect signal at parts-per-million, in samples your current platform may call negative.
02
Flexibility
You choose: send samples to our accredited lab, or run SiMSen-Seq on your own instruments.
03
Clinical insight
You see actionable variants and tumour evolution, not just a binary positive or negative.
04
Transparency
You get full raw data access and an open analysis pipeline. Your bioinformatics team can verify, reanalyse or extend our results with their own tools.
05
Partnership
You work with a specialist team: co-publication, protocol design and interpretation help.
Read the platform in whichever order serves you.
Each of the four pages below is written for a different visitor. Start where you are. Each takes about three minutes to read.
———
01 / Why Simsen
The five reasons people choose us.
If you are deciding whether to talk to us at all.
The five benefit-framed pillars that run through everything: sensitivity, flexibility, clinical insight , transparency partnership. The shortest route to whether we are worth a conversation.
———
02 / Technology
The science under the hood.
If you already understand ctDNA and want the details.
Barcoded duplex sequencing, error suppression, validated sensitivity down to single molecules. Performance data, the sample-to-result workflow, and the limitations we are open about.
———
01 / Why Simsen
The five reasons people choose us.
If you are deciding whether to talk to us at all.
The five benefit-framed pillars that run through everything: sensitivity, flexibility, clinical insight , transparency partnership. The shortest route to whether we are worth a conversation.
———
02 / Technology
The science under the hood.
If you already understand ctDNA and want the details.
Barcoded duplex sequencing, error suppression, validated sensitivity down to single molecules. Performance data, the sample-to-result workflow, and the limitations we are open about.
TRUSTED BY LEADING EUROPEAN CLINICS, HOSPITALS AND BIOTECHS
What ultra-sensitivity looks like for the people doing the work.
|
<0.001% |
9 months |
3-5 ppm |
| Variant allele frequency you can detect, in your own samples. | Earlier than imaging picked up relapse, in paediatric sarcoma monitoring. |
Residual ctDNA you can see three days after pancreatic surgery. |
| SIMSEN-SEQ, NATURE PROTOCOLS → | EK ET AL., 2024 → | PRELIMINARY, STUDY ONGOING → |
Three ways to monitor ctDNA. They are not interchangeable.
Tumour-informed monitoring splits broadly into three approaches: tracking single nucleotide variants, tracking structural variants, or using fixed tumour-naive panels. Each has consequences for your samples. Most platforms hide this choice. We think it deserves daylight.
———
|
SIMSEN APPROACH |
|
Personalised and ultra-sensitive, surfacing clinically actionable variants alongside tumour markers. |
|
|
Best when: small biopsies, low tumour burden, you want resistance signal. |
|
———
|
|
|
Personalised, sensitive in tumour types with high structural-variant burden, but no resistance information. |
|
|
Best when: SV-rich tumours, resistance tracking not required. |
|
———
|
|
|
Fixed panel, no biopsy needed, lower sensitivity at very low allele frequencies. |
|
|
Best when: No tissue available, sensitivity is secondary. |
|